Filing Flows › Haemonetics (HAE) › Q1 FY27 › vs Q1 FY26
Haemonetics (HAE) Q1 FY27 vs Q1 FY26 (year over year)
Haemonetics's revenue rose $18.0M (+6%) from $321M in Q1 FY26 to $339M in Q1 FY27. The biggest changes: Apheresis +$9.6M (+5%); MedSurg +$8.4M (+6%). Gross margin 59.8% against 59.8% (-0.1 pts).
Haemonetics, Q1 FY27: revenue $339M (+6% year over year), operating margin 16.9%, net earnings $33.0M, operating cash flow $52.3M. The chart draws each line against Q1 FY26, the increases inside each band.
Margins
| Q1 FY27 | Q1 FY26 | Change | |
|---|---|---|---|
| Gross margin | 59.8% | 59.8% | -0.1 pts |
| Operating margin | 16.9% | 16.8% | +0.2 pts |
| Net margin | 9.7% | 10.6% | -0.9 pts |
Every line
| Line | Q1 FY27 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Apheresis | $191M | $182M | $9.6M | +5% |
| MedSurg | $148M | $140M | $8.4M | +6% |
| Revenue | $339M | $321M | $18.0M | +6% |
| Gross profit | $203M | $192M | $10.6M | +5% |
| Cost of revenue | $137M | $129M | $7.4M | +6% |
| Operating profit | $57.5M | $53.9M | $3.6M | +7% |
| Operating expenses | $145M | $138M | $7.0M | +5% |
| Pre-tax earnings | $47.6M | $45.2M | $2.4M | +5% |
| Other expense, net | $9.9M | $8.7M | $1.2M | +14% |
| Research & development | $16.2M | $16.3M | −$61K | -0.4% |
| SG&A | $119M | $111M | $8.2M | +7% |
| Other operating costs | $10.2M | $11.4M | −$1.2M | -10% |
| Net earnings | $33.0M | $34.0M | −$1.0M | -3% |
| Income tax | $14.6M | $11.1M | $3.4M | +31% |
| Depreciation & amortization | $27.1M | $28.8M | −$1.6M | -6% |
| Share-based compensation | $9.3M | $9.3M | −$1K | 0% |
| Working capital & other | $17.1M | $54.7M | −$37.6M | -69% |
| Operating cash flow | $52.3M | $17.4M | $34.9M | +201% |
Questions
How much did Haemonetics's revenue grow year over year in Q1 FY27?
Haemonetics's revenue rose $18.0M (+6%) from $321M in Q1 FY26 to $339M in Q1 FY27.
What drove Haemonetics's revenue change in Q1 FY27?
Apheresis +$9.6M (+5%); MedSurg +$8.4M (+6%).